EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Determination of the Apoptotic Effect of Raf2 and Nck-Interacting Protein Kinase Inhibitor on Metastatic Canine Mammary Gland Tumor Cells

Asuman DEVECİ ÖZKAN, Ayten HACIEFENDİ, Fatih ÖZKAN, Gamze GÜNEY ESKİLER, Süleyman KALELİ, Ecir Ali ÇAKMAK, Özge TURNA

Online Türk Sağlık Bilimleri Dergisi · 2022

DOI: 10.26453/otjhs.1036628 ↗
AbstractBibliografische Angaben

Abstract

Objective: Canine mammary gland tumors (CMGTs) are the most common tumors in female dogs and the main treatment options used in CMGTs are surgery caused some complications. Therefore, new treatment options are needed for the CMGTs. Traf2 and Nck-interacting serine protein kinase (TNIK) as a transcriptional coregulator of Wnt targeted genes is highly expressed in breast cancer development. The inhibition of TNIK may be a new therapeutic target in cancers with abnormal WNT signaling. Therefore we aimed to investigate the potential therapeutic effect of NCB-0846 on metastatic sarcoma CMGTs subtype, for the first time. Materials and Methods: The cytotoxic and apoptotic effects of NCB-0846 on CMGT cells were analyzed by WST‑1, Annexin V, cell cycle, acridine orange (AO) and DAPI staining. Results: NCB-0846 significantly inhibited cell viability in a dose and time dependent manner (p<0.05) and induced nuclear damage in CMGT cells. Furthermore, NCB-0846 caused apoptotic cell death through the accumulation of cells in the G0/G1 phase. Conclusion: Our findings demonstrated that NCB-0846 could be potentially a new therapeutic anti-cancer agent in the treatment of CMGTs. However, further investigations need to be performed in order to elucidate the inhibitory activity of TNIK and Wnt signaling by NCB-0846 on CMGT cells.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →